NCT05710211Recruiting
Clonal Architecture of ASXL1-mutated Myelofibrosis
Source: ClinicalTrials.gov · Last updated 9 Mar 2026
Brief summary (registry, in English)
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 28 Dec 2022
- Start date
- 24 Apr 2023
- Primary completion date
- 23 Apr 2027
- Lead sponsor
- University Hospital, Angers
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05710211
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 24 Apr 2023 to the primary completion date, 23 Apr 2027
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with another active hematological disease or cancer at the time of diagnosis,
Other
- Person subject to legal protection scheme or incapable of giving consent.
Who the study is looking for
- Adults (age ≥18 years),
- Affiliated to the national social security system,
- ASXL1 mutated primary or secondary myelofibrosis,
- Signed the consent to participate in the study,
- Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.